Scope of the Report
The report entitled “Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020)” provides an analysis of the global anticoagulants market with detailed description of market size & growth and market share by products.
The report also provides a detailed analysis of anticoagulants available in the market. Details of Lovenox, Arixtra, Fraxiparine (injectable anticoagulants), Xarelto, Pradaxa and Eliquis (NOACs) has provided in terms of their worldwide sales.
The report provides detailed regional analysis of the US anticoagulants market covering market size and segmentation of the market.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2016-2020, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
A brief company profiling of major market players such as Aspen, Snaofi, Pfizer and Bayer has been provided in the report on the basis of attributes like business overview, financial overview and business strategies adopted by these companies in order to grow in the market.
- The US
- Aspen Pharmacare Holdings Ltd.
- Pfizer Inc.
Usually blood clotting plays a significant role in stopping external bleeding caused by an injury but when blood clots form inappropriately inside an artery or vein can cause serious issues such as heart attack and stroke. The formation of clots in blood vessels can stop the circulation of blood in the body that can even lead to death. So an agent is used that helps to eradicate the formation of blood clots in the body and is known as anticoagulant. Anticoagulants stop the platelets from sticking together and clotting proteins from binding together. Anticoagulants are popular drugs used in the treatment of deep vein thrombosis (DVT), atrial fibrillation, pulmonary embolism (PE) and reducing the risk of heart attack and brain stroke.
Due to the dynamics like rising aging population, more surgical procedures like knee or hip replacement in developed nations and prevalence of cardiovascular disease etc.; the global anticoagulants market is growing rapidly. There are two types of anticoagulants available in the market: oral and injectable. Anticoagulants market is categorized into five broad categories: unfractionated heparin, warfarin, low molecular weight heparin (LMWH), factor XA inhibitors and direct thrombin inhibitors. Among these, unfractionated heparin and LMWH are widely used injectable anticoagulants. LMWH are more convenient to use as these can be self-injected at home. Warfarin is an oral anticoagulant that has been used traditionally for patient suffering from atrial fibrillation.
The global anticoagulants market has increased with healthy growth rates over the years and is expected to grow further during the forecasted period (2016-2020). The global anticoagulant market is supported by a number of growth drivers such as increasing prevalence of deep vein thrombosis (DVT) & pulmonary embolism, rising aging population, increasing R&D expenses by pharmaceutical companies and rising cardiovascular diseases etc. Yet the market faces some challenges such as patent expiration of some popular anticoagulants like warfarin, stringent regulations by government and a number of side effects associated with the drugs.
2.1 Overview of Anticoagulants
2.1.1 Categories of Anticoagulants
Low molecular weight heparins (LMWH)
Factor XA inhibitors
Direct thrombin inhibitors (DTIs)
2.1.2 Novel Oral Anticoagulants (NOACs)
3. Global Market Analysis
3.1 Global Anticoagulants Market: An Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market by Products
4. Product Analysis
4.1 Injectable Anticoagulants
4.1.1 Lovenox (Enoxaparin Sodium)
4.1.2 Nadroparin (Fraxiparine)
4.1.3 Arixtra (Fondaparinux Sodium)
4.2 Oral Anticoagulants
4.2.1 Xarelto (Rivaroxaban)
4.2.2 Pradaxa (Dabigatran)
4.2.3 Eliquis (Apixaban)
5. Country/Regional Analysis
5.1 The US Anticoagulants Market
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Anticoagulants Market by Segment
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Increasing Knee Replacement Surgery
6.1.2 Rising Number of Hip Replacement Surgery
6.1.3 Rising Aging Population
6.1.4 Increasing R&D Drug Spending
6.1.5 Prevalence of Cardiovascular Diseases
6.1.6 Growing Awareness over Anticoagulants
6.1.7 Increasing Incidence of Pulmonary Embolism
6.2.1 Patent Expiration
6.2.2 Stringent Regulations
6.2.3 Risk of Side-Effects
6.2.4 Complications Associated with Oral Anticoagulants
6.3 Market Trends
6.3.1 Introduction of Novel Oral Anticoagulants
6.3.2 Increasing Number of Mergers & Acquisitions
6.3.3 Generic Prevalence in Traditional Market
6.3.4 Growing Demand for Self-Management
7. Competitive Landscape
8. Company Profiling
8.1 Aspen Pharmacare Holdings Ltd.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Pfizer Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
Figure1: Categories of Anticoagulants
Table 1: List of Intravenous/Subcutaneous Anticoagulants
Table 2: List of Oral Anticoagulants (NOCAs)
Figure 2: Global Anticoagulants Market by Value; 2013-2015E (US$ Billion)
Figure 3: Global Anticoagulants Market by Value; 2016-2020E (US$ Billion)
Figure 4: Global Anticoagulants Market Share by Products; 2014
Figure 5: Lovenox Global Sales; 2011-2015 (US$ Billion)
Figure 6: Nadroparin Global Sales; 2010-2015E (US$ Million)
Figure 7: Arixtra Global Sales; 2010-2015E (US$ Million)
Figure 8: Xarelto Global Sales; 2011-2015E (US$ Billion)
Figure 9: Pradaxa Global Sales; 2010-2015E (US$ Billion)
Figure 10: Eliquis Global Sales; 2013-2015E (US$ Million)
Figure 11: The US Anticoagulants Market by Value; 2012-2015E (US$ Billion)
Figure 12: The US Anticoagulants Market by Value; 2016-2020E (US$ Billion)
Figure 13: The US Anticoagulants Market by Segment; 2015
Figure 14: Knee Replacement per 100000 Population; 2014
Figure 15: Hip Replacement per 100000 Population; 2014
Figure 16: Aging Population; 2000-2015 (Million)
Figure 17: R&D Drug Spending; 2014-2020E (US$ Billion)
Figure 18: Distribution of Major Causes of Death; 2014
Table 3: Sales of Top Oral Anticoagulants Players in the Market (US$ Billion)
Figure 19: Aspen Revenue; 2011-2015 (US$ Billion)
Figure 20: Aspen Revenue Share by Geography; 2015
Figure 21: Sanofi Revenue; 2011-2015 (US$ Billion)
Figure 22: Sanofi Revenue by Segment; 2015
Figure 23: Pfizer Inc. Revenue; 2011-2015 (US$ Billion)
Figure 24: Pfizer Inc. Revenue Share by Geography; 2015
Figure 25: Bayer Revenue; 2011-2015 (US$ Billion)
Figure 26: Bayer Revenue Share by Segment; 2014